Agios sells vorasidenib royalty rights to Royalty Pharma for $905M

Vorasidenib, which treats IDH-mutant diffuse glioma, showed efficacy in data released last year.

Related Keywords

Brian Goff ,Pablo Legorreta ,Drug Administration ,Agios Pharmaceuticals ,Royalty Pharma ,Prescription Drug User Fee Act ,